Organogenesis Holdings Inc. (ORGO) Revenue by Segment & Business Profile
Product was 97.8% of Organogenesis Holdings Inc.'s revenue across the 2 lines it reports, according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
ORGOOrganogenesis Holdings Inc.Follow ORGO — free
—
Price chart with a free account
- Market cap
- 127.8M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 5 Nov, in 11 days
What the company does
Organogenesis Holdings Inc. is a drug manufacturers - specialty & generic company in the healthcare sector. In its SEC filings it reports 2 business lines: Product (98%), Grant (2%). Trailing twelve-month revenue: $457.5 million as of 2026-06-30.
Roles we read
from the filings, not the sector label- Orthobiologics / joint preservation
Organogenesis Holdings Inc. — questions
- What does Organogenesis Holdings Inc. do?
- Organogenesis Holdings Inc. is a drug manufacturers - specialty & generic company in the healthcare sector. In its SEC filings it reports 2 business lines: Product (98%), Grant (2%). Trailing twelve-month revenue: $457.5 million as of 2026-06-30.
- How does Organogenesis Holdings Inc. make money?
- By the lines it reports in its SEC filings: Product 97.8%, Grant 2.2% of revenue.
Every figure on this page comes from Organogenesis Holdings Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.